Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

434 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study.
Chan JK, Tian C, Kesterson JP, Richardson MT, Lin K, Tewari KS, Herzog T, Kapp DS, Monk BJ, Casablanca Y, Hanjani P, Wenham RM, Walker J, McNally L, Copeland LJ, Robertson S, Lentz S, Spirtos NM, Bell JG. Chan JK, et al. Among authors: lentz s. Gynecol Oncol. 2022 Dec;167(3):429-435. doi: 10.1016/j.ygyno.2022.09.028. Epub 2022 Oct 14. Gynecol Oncol. 2022. PMID: 36244828 Clinical Trial.
What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer.
Pitiyarachchi O, Friedlander M, Java JJ, Chan JK, Armstrong DK, Markman M, Herzog TJ, Monk BJ, Backes F, Secord AA, Bonebrake A, Rose PG, Tewari KS, Lentz SS, Geller MA, Copeland LJ, Mannel RS. Pitiyarachchi O, et al. Among authors: lentz ss. Gynecol Oncol. 2022 Sep;166(3):410-416. doi: 10.1016/j.ygyno.2022.07.004. Epub 2022 Jul 11. Gynecol Oncol. 2022. PMID: 35835612 Free PMC article.
A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q).
Herzog TJ, Sill MW, Walker JL, O'Malley D, Shahin M, DeGeest K, Weiner SA, Mutch D, DeBernardo RL, Lentz SS. Herzog TJ, et al. Among authors: lentz ss. Gynecol Oncol. 2011 Mar;120(3):454-8. doi: 10.1016/j.ygyno.2010.11.008. Epub 2010 Dec 17. Gynecol Oncol. 2011. PMID: 21168198 Clinical Trial.
Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173.
Coleman RL, Ali S, Levenback CF, Gold MA, Fowler JM, Judson PL, Bell MC, De Geest K, Spirtos NM, Potkul RK, Leitao MM Jr, Bakkum-Gamez JN, Rossi EC, Lentz SS, Burke JJ 2nd, Van Le L, Trimble CL. Coleman RL, et al. Among authors: lentz ss. Gynecol Oncol. 2013 Feb;128(2):155-9. doi: 10.1016/j.ygyno.2012.11.034. Epub 2012 Nov 29. Gynecol Oncol. 2013. PMID: 23201592 Free PMC article. Clinical Trial.
Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study.
Berek JS, Edwards RP, Parker LP, DeMars LR, Herzog TJ, Lentz SS, Morris RT, Akerley WL, Holloway RW, Method MW, Plaxe SC, Walker JL, Friccius-Quecke H, Krasner CN. Berek JS, et al. Among authors: lentz ss. Int J Gynecol Cancer. 2014 Nov;24(9):1583-9. doi: 10.1097/IGC.0000000000000286. Int J Gynecol Cancer. 2014. PMID: 25254563 Clinical Trial.
A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study.
Coleman RL, Brady WE, McMeekin DS, Rose PG, Soper JT, Lentz SS, Hoffman JS, Shahin MS. Coleman RL, et al. Among authors: lentz ss. Gynecol Oncol. 2011 Jul;122(1):111-5. doi: 10.1016/j.ygyno.2011.03.036. Epub 2011 Apr 15. Gynecol Oncol. 2011. PMID: 21497382 Free PMC article. Clinical Trial.
434 results